Overview/Mission‹berblick und Mission
    Home
    t2cureís cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.

    Overview/Mission

    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases.

    t2cure is a biopharmaceutical company founded by Prof. Andreas M. Zeiher and Prof. Stefanie Dimmeler, both internationally renowned academic researchers at Frankfurt University. The founders of t2cure developed a therapeutic approach to effectively induce neo-vascularization and repair processes in ischemic tissue. The new therapeutics consist of autologous progenitor cells prepared from a patientís own bone marrow. These progenitor cells have the potential to induce repair and healing processes in cardiac or peripheral tissues. The cells are administered via catheter into the coronary arteries of a diseased heart or into peripheral arteries of a diseased limb in a routine procedure.

    Glossary